Poster

Purification Of A Recombinant Monoclonal Antibody – Rituximab Biosimilar – With A Non-Affinity Based Chromatographic Process

Protein A resins have two major disadvantages, high cost and low resin stability. We evaluated the purification of the recombinant antibody rituximab using a non–Protein A purification scheme. This included a cation exchange (CEX) resin for capture purification, followed by anion exchange (AEX) resin for intermediate, and a hydroxyapatite (mixed mode) media for polish purification. Simultaneous purification was performed with a Protein A workflow. The CEX – AEX – mixed-mode resins workflow was economical and yielded >99% purity and 80% yield of rituximab. Host cell protein (HCP) levels were reduced by four logs and host cell cDNA (hcDNA) levels by 5 logs after the final purification step. A pharmacokinetic bridging assay suggests that the purified monoclonal antibody behaved in a similar way to a rituximab standard, showing no significant loss of structure or function throughout purification. We therefore propose that a non–affinity based purification workflow for rituximab provides better process economics and uncompromised results.

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Biosimilar Development? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: